Thursday, March 23, 2023
Community Focus: Clinical Advances in
Read Overview
Supported by independent educational grants from Pharmacyclics LLC, An AbbVie Company, Janssen Biotech, Inc., and Genentech.
Steering Committee Chair
Assistant Professor of Medicine
Duke University School of Medicine
Member, Duke Cancer Institute
Durham, North Carolina
Associate Professor
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, Georgia
Associate Professor of Medicine
Harvard Medical School
Director, Clinical Research, Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland
Director
Hematology/Oncology
Piedmont Cancer Institute
Atlanta, Georgia
Assistant Professor of Medicine
Division of Hematology
University of Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Steering Committee Chair
Danielle Marie Brander, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; ArQule/Merck; Genentech; Pfizer; Pharmacyclics; TG Therapeutics
Research funding from: AbbVie; ArQule/Merck; Ascentage Pharma; AstraZeneca/Acerta; BeiGene; Bristol Myers Squibb; CATO SMS; Celgene; DTRM; Genentech; Juno; MEI Pharma; NeWave; Novartis; Pharmacyclics; TG Therapeutics
Other: Biosimilars outcomes research panel for Pfizer; CORE Study (CLL Collaborative Study of Real-World Evidence) for AbbVie; informCLL registry steering committee for AbbVie and Pharmacyclics
Steering Committee Member
Jonathon Cohen, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Aptitude Health; AstraZeneca; BeiGene; HUTCHMED; Janssen; Kite/Gilead; Loxo/Lilly
Research funding from: AstraZeneca; BeiGene; Bristol Myers Squibb/Celgene; BioInvent; Genentech; Loxo/Lilly; Novartis; Takeda
Steering Committee Member
Matthew Davids, MD, MMSc, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Adaptive Biotechnologies; Aptitude Health; Ascentage Pharma, AstraZeneca; BeiGene; Bristol Myers Squibb; Celgene; Eli Lilly; Genentech; Janssen; MEI Pharma; Merck; ONO Pharmaceuticals; Pharmacyclics; Takeda; TG Therapeutics; Verastem
Research funding from: Ascentage Pharma; AstraZeneca; Genentech; MEI Pharma; Novartis; Pharmacyclics; Surface Oncology; TG Therapeutics; Verastem
Steering Committee Member
Amy L. Goodrich, RN, MSN, CRNP-AC, has no relevant financial relationships.
Steering Committee Member
William S. Jonas, MD, has no relevant financial relationships.
Steering Committee Member
Deborah Stephens, DO, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; BeiGene; Bristol Myers Squibb; Celgene; CSL Behring; Eli Lilly; Genentech; TG Therapeutics
Research funding from: Acerta; ArQule; AstraZeneca; Juno; MingSight; NeWave; Novartis
